Home

Our Approach

Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Learn More ButtonLearn More Button

Pipeline

The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.

View Pipeline ButtonPipeline View Button

Clinical Trials

We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.

Find Out More ButtonFind Out More Button

News

ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial

ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland, August 6, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine,

ADC Therapeutics Announces Final Close of Series E Financing Expansion

ADC Therapeutics Announces Final Close of Series E Financing Expansion
$103 million raised in Series E expansion, including a new U.S.-based institutional investor, brings total Series E proceeds to $303 million Lausanne, Switzerland, July 9, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced the final close of a $103 million

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019 Pivotal Phase II clinical trial of ADCT-301 in relapsed or refractory Hodgkin lymphoma expected to commence in coming months Lausanne, Switzerland, June 21, 2019 – ADC Therapeutics, an